IDSA Statement on Increase in Monkeypox Vaccine Supply

Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.

As monkeypox cases in the United States top more than 4,600, having the vaccine doses to serve people in need is important, but it is only part of the solution. The United States must continue to ramp up vaccine supply and must move swiftly to implement a comprehensive distribution approach to significantly increase equitable access to vaccines. Distribution should leverage existing vaccine infrastructure, including safety net and mobile clinics as well as partnerships with community-based organizations.

The monkeypox outbreak is growing exponentially by the day. IDSA and HIVMA urge the Administration to continue to improve vaccine distribution and supply and reduce barriers to testing and treatment.

Daniel P. McQuillen, MD, FIDSA – President, Infectious Diseases Society of America

About IDSA and HIVMA 
IDSA is a leader on issues of importance to ID professionals, including education and training, policy and advocacy, setting guidelines for patient care, and developing resources for clinical practice. It remains at the forefront of global health issues such as COVID-19, antimicrobial resistance and HIV/AIDS. Housed within IDSA is the HIV Medicine Association, (HIVMA) which represents medical providers and researchers working on the front lines of HIV. More than 12,000 IDSA and HIVMA members work across the United States and in nearly 100 other countries on six different continents. For more information visit  www.idsociety.org. Follow IDSA on Facebook and Twitter.